Ischemic And Bleeding Risk Assessment After TAVR
Launched by NIGUARDA HOSPITAL · Aug 13, 2023
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the risks of blood clots and bleeding in patients who undergo a procedure called Transcatheter Aortic Valve Replacement (TAVR) for severe aortic valve narrowing, a condition known as aortic stenosis. The goal is to better understand how different types of blood-thinning treatments and the patient's overall health can affect these risks after the procedure. Researchers are looking at how the type of valve used and certain blood test results can influence the likelihood of complications over time.
To participate in this trial, you must be an adult with severe aortic stenosis who is scheduled for TAVR. The study will track changes in your blood-thinning treatment at specific times after the procedure—at one month, three months, and one year. It's important to know that patients who do not survive the initial procedure or those on a specific type of blood-thinning therapy will not be eligible. Participants can expect regular follow-ups and monitoring to assess their health and any changes in their treatment plan.
Gender
ALL
Eligibility criteria
- • Inclusion criteria
- • All patients with severe aortic stenosis undergoing TAVR.
- • Availability of changes in antithrombotic therapy at 1 month, 90 days, and 1 year after TAVR.
- • Exclusion Criteria
- • Patients who died during the index procedure
- • Patients in triple antithrombotic therapy at discharge
- • Patients with a known prognosis less than 1 year at the time of TAVR
About Niguarda Hospital
Niguarda Hospital, located in Milan, Italy, is a leading healthcare institution renowned for its commitment to innovative medical research and high-quality patient care. As a prominent clinical trial sponsor, Niguarda Hospital actively engages in multidisciplinary studies aimed at advancing medical knowledge and improving therapeutic outcomes across various specialties. The hospital's state-of-the-art facilities and a team of experienced researchers and clinicians foster a collaborative environment that prioritizes ethical standards and patient safety. Niguarda Hospital is dedicated to translating research findings into clinical practice, ultimately enhancing the standard of care for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Donato Milanese, Milano, Italy
Roma, , Italy
Aalst, , Belgium
Prague, , Czechia
Torino, , Italy
Rozzano, Milano, Italy
Genova, , Italy
Milano, Italia, Italy
Genova, Ge, Italy
Santiago, , Chile
Avellino, , Italy
Milano, , Italy
Potenza, , Italy
Cadiz, , Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported